BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Prognosis
7252 results:

  • 1. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
    Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
    BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Human epididymis protein 4, a novel potential biomarker for diagnostic and prognosis monitoring of lung cancer.
    Zhang T; Chu L; Tan W; Ye C; Dong H
    Clin Respir J; 2024 May; 18(5):e13774. PubMed ID: 38742362
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
    Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
    [No Abstract]    [Full Text] [Related]  

  • 5. Prediction of Prognostic Features Based on Neutrophil-Related Genes for lung Squamous Cell Carcinoma Reveals Immune Landscape and Drug Candidates.
    Sili D; Nan Z
    Rev Invest Clin; 2024; 76(2):116-131. PubMed ID: 38740381
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Transcript and protein signatures derived from shared molecular interactions across cancers are associated with mortality.
    Zhao Y; Li X; Loscalzo J; Smelik M; Sysoev O; Wang Y; Mahmud AKMF; Mansour Aly D; Benson M
    J Transl Med; 2024 May; 22(1):444. PubMed ID: 38734658
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. High incidence of lung cancer death after curative endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma.
    Tajiri A; Tsujii Y; Nishida T; Inoue T; Maekawa A; Kitamura S; Yamaguchi S; Nishihara A; Yamada T; Ogiyama H; Murayama Y; Yamamoto S; Egawa S; Uema R; Yoshihara T; Hayashi Y; Takehara T
    Cancer Med; 2024 May; 13(9):e7242. PubMed ID: 38733176
    [TBL] [Abstract] [Full Text] [Related]  

  • 8.
    Feng B; Wang X; Qiu D; Sun H; Deng J; Tan Y; Ji K; Xu S; Zhang S; Tang C
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732173
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation.
    Xiao B; Li G; Gulizeba H; Liu H; Sima X; Zhou T; Huang Y
    J Transl Med; 2024 May; 22(1):442. PubMed ID: 38730286
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell lung cancer.
    Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
    JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
    J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Carbon ion radiotherapy for mesonephric adenocarcinoma of the uterine cervix: a case report.
    Kobayashi N; Oike T; Ando K; Murata K; Tamaki T; Noda SE; Kogure K; Nobusawa S; Oyama T; Ohno T
    J Med Case Rep; 2024 May; 18(1):228. PubMed ID: 38720351
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Prognostic Implications of Small Cell lung cancer Transcriptional Subtyping for CNS Metastases.
    Tringale KR; Skakodub A; Egger J; Eichholz J; Yu Y; Gomez D; Rimner A; Li B; Yamada Y; Wilcox J; Moss N; Imber BS; Rekhtman N; Baine MK; Rudin CM; Pike LRG
    JCO Precis Oncol; 2024 Apr; 8():e2300470. PubMed ID: 38691815
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A retrospective clinical analysis of 11 cases of PEComa from different sites.
    Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
    World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The impact of COVID-19 on the prognosis of deep vein thrombosis following anticoagulation treatment: a two-year single-center retrospective cohort study.
    Wang Q; Wu J; Zhang P; Ma X
    BMC Pulm Med; 2024 Apr; 24(1):208. PubMed ID: 38671424
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
    Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
    J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The value of lung function assessment and Testin expression detection in clinicopathological features and prognosis of NSCLC patients.
    Zhang Y; Wang G; Zhang Q; Wang Q; Luo J; Ling C
    J Cardiothorac Surg; 2024 Apr; 19(1):223. PubMed ID: 38627776
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Dichotomous Effects of Glypican-4 on cancer Progression and Its Crosstalk with Oncogenes.
    Chérouvrier Hansson V; Cheng F; Georgolopoulos G; Mani K
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612755
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. YAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma.
    Papavassiliou KA; Sofianidi AA; Papavassiliou AG
    J Cell Mol Med; 2024 Apr; 28(8):e18330. PubMed ID: 38606782
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 363.